Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1997 Jan 15;25(2):370–378. doi: 10.1093/nar/25.2.370

Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.

E R Kandimalla 1, A Manning 1, Q Zhao 1, D R Shaw 1, R A Byrn 1, V Sasisekharan 1, S Agrawal 1
PMCID: PMC146429  PMID: 9016567

Abstract

We have designed and synthesized mixed backbone oligonucleotides (MBOs) containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments. Thermal melting studies of the phosphodiester MBOs (three 2'-5'linkages at each end) with the complementary 3'-5'-DNA and -RNA target strands suggest that 2'-5'-ribonucleoside incorporation into 3'-5'-oligodeoxyribonucleotides reduces binding to the target strands compared with an all 3'-5'-oligodeoxyribonucleotide of the same sequence and length. Increasing the number of 2'-5'linkages (from six to nine) further reduces binding to the DNA target strand more than the RNA target strand [Kandimalla,E.R. and Agrawal,S. (1996)Nucleic Acids Symp. Ser., 35, 125-126]. Phosphorothioate (PS) analogs of MBOs destabilize the duplex with the DNA target strand more than the duplex with the RNA target strand. Circular dichroism studies indicate that the duplexes of MBOs with the DNA and RNA target strands have spectral characteristics of both A- and B-type conformations. Compared with the control oligonucleotide, MBOs exhibit moderately higher stability against snake venom phosphodiesterase, S1 nuclease and in fetal calf serum. Although 2'-5'modification does not evoke RNase H activity, this modification does not effect the RNase H activation property of the 3'-5'-deoxyribonucleotide segment adjacent to the modification. In vitro studies with MBOs suggest that they have lesser effects on cell proliferation, clotting prolongation and hemolytic complement lysis than do control PS oligodeoxyribonucleotides. PS analogs of MBOs show HIV-1 inhibition comparable with that of a control PS oligodeoxyribonucleotide with all 3'-5'linkages. The current results suggest that a limited number of 2'-5'linkages could be used in conjunction with PS oligonucleotides to further modulate the properties of antisense oligonucleotides as therapeutic agents.

Full Text

The Full Text of this article is available as a PDF (207.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996 Oct;14(10):376–387. doi: 10.1016/0167-7799(96)10053-6. [DOI] [PubMed] [Google Scholar]
  2. Agrawal S., Goodchild J., Civeira M. P., Thornton A. H., Sarin P. S., Zamecnik P. C. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7079–7083. doi: 10.1073/pnas.85.19.7079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Agrawal S., Ikeuchi T., Sun D., Sarin P. S., Konopka A., Maizel J., Zamecnik P. C. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci U S A. 1989 Oct;86(20):7790–7794. doi: 10.1073/pnas.86.20.7790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Agrawal S., Mayrand S. H., Zamecnik P. C., Pederson T. Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1401–1405. doi: 10.1073/pnas.87.4.1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Agrawal S., Rustagi P. K., Shaw D. R. Novel enzymatic and immunological responses to oligonucleotides. Toxicol Lett. 1995 Dec;82-83:431–434. doi: 10.1016/0378-4274(95)03573-7. [DOI] [PubMed] [Google Scholar]
  6. Agrawal S., Temsamani J., Galbraith W., Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7–16. doi: 10.2165/00003088-199528010-00002. [DOI] [PubMed] [Google Scholar]
  7. Bayever E., Iversen P. L., Bishop M. R., Sharp J. G., Tewary H. K., Arneson M. A., Pirruccello S. J., Ruddon R. W., Kessinger A., Zon G. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993 Winter;3(4):383–390. doi: 10.1089/ard.1993.3.383. [DOI] [PubMed] [Google Scholar]
  8. Cedergren R., Grosjean H. RNA design by in vitro RNA recombination and synthesis. Biochem Cell Biol. 1987 Aug;65(8):677–692. doi: 10.1139/o87-090. [DOI] [PubMed] [Google Scholar]
  9. Crooke S. T., Grillone L. R., Tendolkar A., Garrett A., Fratkin M. J., Leeds J., Barr W. H. A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):641–646. doi: 10.1038/clpt.1994.189. [DOI] [PubMed] [Google Scholar]
  10. Farrell P. J., Sen G. C., Dubois M. F., Ratner L., Slattery E., Lengyel P. Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A. 1978 Dec;75(12):5893–5897. doi: 10.1073/pnas.75.12.5893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Floyd-Smith G., Slattery E., Lengyel P. Interferon action: RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease. Science. 1981 May 29;212(4498):1030–1032. doi: 10.1126/science.6165080. [DOI] [PubMed] [Google Scholar]
  12. Galbraith W. M., Hobson W. C., Giclas P. C., Schechter P. J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev. 1994 Fall;4(3):201–206. doi: 10.1089/ard.1994.4.201. [DOI] [PubMed] [Google Scholar]
  13. Giannaris P. A., Damha M. J. Oligoribonucleotides containing 2',5'-phosphodiester linkages exhibit binding selectivity for 3',5'-RNA over 3',5'-ssDNA. Nucleic Acids Res. 1993 Oct 11;21(20):4742–4749. doi: 10.1093/nar/21.20.4742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jin R., Chapman W. H., Jr, Srinivasan A. R., Olson W. K., Breslow R., Breslauer K. J. Comparative spectroscopic, calorimetric, and computational studies of nucleic acid complexes with 2',5"-versus 3',5"-phosphodiester linkages. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10568–10572. doi: 10.1073/pnas.90.22.10568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Joyce G. F. Nonenzymatic template-directed synthesis of informational macromolecules. Cold Spring Harb Symp Quant Biol. 1987;52:41–51. doi: 10.1101/sqb.1987.052.01.008. [DOI] [PubMed] [Google Scholar]
  16. Kandimalla E. R., Manning A., Lathan C., Byrn R. A., Agrawal S. Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides. Nucleic Acids Res. 1995 Sep 11;23(17):3578–3584. doi: 10.1093/nar/23.17.3578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kerr I. M., Brown R. E. pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci U S A. 1978 Jan;75(1):256–260. doi: 10.1073/pnas.75.1.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546–549. doi: 10.1038/374546a0. [DOI] [PubMed] [Google Scholar]
  19. Lesiak K., Imai J., Floyd-Smith G., Torrence P. F. Biological activities of phosphodiester linkage isomers of 2-5A. J Biol Chem. 1983 Nov 10;258(21):13082–13088. [PubMed] [Google Scholar]
  20. Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J. S., Broder S. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7706–7710. doi: 10.1073/pnas.84.21.7706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Padgett R. A., Konarska M. M., Grabowski P. J., Hardy S. F., Sharp P. A. Lariat RNA's as intermediates and products in the splicing of messenger RNA precursors. Science. 1984 Aug 31;225(4665):898–903. doi: 10.1126/science.6206566. [DOI] [PubMed] [Google Scholar]
  22. Puglisi J. D., Tinoco I., Jr Absorbance melting curves of RNA. Methods Enzymol. 1989;180:304–325. doi: 10.1016/0076-6879(89)80108-9. [DOI] [PubMed] [Google Scholar]
  23. Ratmeyer L., Vinayak R., Zhong Y. Y., Zon G., Wilson W. D. Sequence specific thermodynamic and structural properties for DNA.RNA duplexes. Biochemistry. 1994 May 3;33(17):5298–5304. doi: 10.1021/bi00183a037. [DOI] [PubMed] [Google Scholar]
  24. Sands H., Gorey-Feret L. J., Cocuzza A. J., Hobbs F. W., Chidester D., Trainor G. L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932–943. [PubMed] [Google Scholar]
  25. Sarin P. S., Agrawal S., Civeira M. P., Goodchild J., Ikeuchi T., Zamecnik P. C. Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7448–7451. doi: 10.1073/pnas.85.20.7448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schatz O., Mous J., Le Grice S. F. HIV-1 RT-associated ribonuclease H displays both endonuclease and 3'----5' exonuclease activity. EMBO J. 1990 Apr;9(4):1171–1176. doi: 10.1002/j.1460-2075.1990.tb08224.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Seki J., Kuroda K., Ozaki H., Sawai H. Double and triple helix formation of 2'-5' and 3'-5' oligonucleotides. Nucleic Acids Symp Ser. 1993;(29):71–72. [PubMed] [Google Scholar]
  28. Smith C. C., Aurelian L., Reddy M. P., Miller P. S., Ts'o P. O. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc Natl Acad Sci U S A. 1986 May;83(9):2787–2791. doi: 10.1073/pnas.83.9.2787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Usher D. A., McHale A. H. Hydrolytic stability of helical RNA: a selective advantage for the natural 3',5'-bond. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1149–1153. doi: 10.1073/pnas.73.4.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zhang R., Diasio R. B., Lu Z., Liu T., Jiang Z., Galbraith W. M., Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol. 1995 Mar 30;49(7):929–939. doi: 10.1016/0006-2952(95)00010-w. [DOI] [PubMed] [Google Scholar]
  31. Zhang R., Iyer R. P., Yu D., Tan W., Zhang X., Lu Z., Zhao H., Agrawal S. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther. 1996 Aug;278(2):971–979. [PubMed] [Google Scholar]
  32. Zhang R., Lu Z., Zhao H., Zhang X., Diasio R. B., Habus I., Jiang Z., Iyer R. P., Yu D., Agrawal S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem Pharmacol. 1995 Aug 8;50(4):545–556. doi: 10.1016/0006-2952(95)00159-w. [DOI] [PubMed] [Google Scholar]
  33. Zhang R., Yan J., Shahinian H. K., Shahinian H., Amin G., Lu Z., Liu T., Saag M. S., Jiang Z., Temsamani J. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther. 1995 Jul;58(1):44–53. doi: 10.1016/0009-9236(95)90071-3. [DOI] [PubMed] [Google Scholar]
  34. Zhao Q., Temsamani J., Iadarola P. L., Jiang Z., Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996 Jan 26;51(2):173–182. doi: 10.1016/0006-2952(95)02177-9. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES